| Patent application number | Description | Published |
|---|
| 20090028804 | AhR mediators - The invention relates to a method for finding and assessing agonists [and] antagonists of the aryl hydrocarbon receptor (Ah receptor; AhR), to the agonists and antagonists themselves and to uses thereof. | 01-29-2009 |
| 20090060876 | Orally Used Compatible Solutes Containing Agents - The invention relates to the use of compatible solutes, especially ectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3 diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), β-mannosylglycerate (firoin), β-mannosylglyceramide (firoin A), proline betaine and/or derivatives as well as combinations thereof for the production of an agent aimed at preventing and treating gastrointestinal and amyloidal diseases, with agents containing said active ingredients being disclosed as well. | 03-05-2009 |
| 20090208432 | AH Receptor Antagonists - The invention relates to the field of aryl hydrocarbon receptor (Ah receptor; AhR) antagonists and their uses. | 08-20-2009 |
| 20090208433 | AH Receptor Antagonists - The invention relates to the field of aryl hydrocarbon receptor (Ah receptor; AhR) antagonists and their uses. | 08-20-2009 |
| 20090311348 | PHARMECEUTICAL AND COSMETIC USE OF SILICA - The invention provides the use of silica for cosmetic and/or medical treatment of skin, including improving and enhancing the skin-barrier, anti-aging treatment and photo-protective treatment. The invention is based on the finding that silica exhibits a multi-faceted biological effect useful in the cosmetic and/or therapeutic treatment of skin for the above purposes. Specifically, it has been shown that silica induces markers (involucrin, filaggrin and transglutaminase-1) for skin barrier formation in keratinocytes, induces collagen expression in dermal fibroblasts and inhibits UVA-induced up-regulation of photo-aging markers (matrix metalloproteinase MMP-1 and cytokine IL-6). | 12-17-2009 |
| 20100028376 | PHARMACEUTICAL AND COSMETIC USE OF EXTRACTS FROM ALGAE OBTAINABLE FROM SALINE HOT WATER SOURCES - The invention provides the use of extracts from algae for cosmetic and/or medical treatment of skin, including improving and enhancing the skin-barrier, anti-aging treatment and photo-protective treatment. The invention is based on the finding that extracts from algae obtainable from saline hot water sources exhibit a multi-faceted biological effect useful in the cosmetic and/or therapeutic treatment of skin for the above purposes. Specifically, it has been shown that such algae extracts induce markers (involucrin, filaggrin and transglutaminase-1) for skin barrier formation in keratinocytes, induce collagen expression in dermal fibroblasts and inhibit UVA-induced up-regulation of photo-aging markers (matrix metalloproteinase MMP-1 and cytokine IL-6). | 02-04-2010 |
| 20100202987 | PREPARATION FOR IMPROVING THE PROTECTION OF HUMAN CELLS, ESPECIALLY CELLS OF THE HUMAN SKIN, FROM THE HARMFUL INFLUENCES OF OXIDATIVE NOXAE AND UV RADIATION - The invention relates to topical preparations for improving the protection of the mitochondria of human skin cells from the deleterious influences of oxidative noxae and UV irradiation, said preparations being characterised by a content in proteins that are capable of permeating the mitochondrial membrane. The invention also relates to a corresponding cosmetic method for treating human skin. | 08-12-2010 |
| 20110053896 | OSMOLYTES FOR THE TREATMENT OF ALLERGIC OR VIRAL RESPIRATORY DISEASES - The present invention relates to the use of osmolytes for treating allergic or viral respiratory diseases, e.g. allergic rhinitis (hay fever) as well as rhinovirus and/or adenovirus infections. The invention also relates to a medicament preparation containing one or more compounds from the group of osmolytes. The group of osmolytes used in the invention comprises various low-molecular substances , more specifically ectoine, 4,5,6,7-tetrahydro-2-methyl-1H-[1, 3]-diazepine-4-S-carboxylic acid (homoectoine), hydroxyectoine, di-myo-inositol-phosphate (DIP), to cyclic 2,3-diphosphoglycerate (cDPG), 1,1-diglycerol phosphate (DGP), β-mannosylglycerate (firoin), β-mannosylglyceramide (firoin-A), dimannosyl-diinositol phosphate (DMIP), glucosylglycerol, taurine, betaine, citrulline, and/or a derivative, e.g. an acid, salt, or ester of said compounds. | 03-03-2011 |
| 20110152294 | USE OF OSMOLYTES OBTAINED FROM EXTREMOPHILIC BACTERIA FOR THE PRODUCTION OF INHALABLE MEDICAMENTS FOR THE PROPHYLAXIS AND TREATMENT OF PULMONARY AND CARDIOVASCULAR DISEASES AND AN INHALATION DEVICE COMPRISING OSMOLYTE AS ACTIVE AGENT COMPONENT - The invention relates to the use of osmolytes, for example, ectoine, hydroxyectoine, firoin, firoin-A, diglycerol phosphate, cyclic diphosphoglycerate, 1,3-dimannosyl-di-myo-inositol-phosphate (DMIP) and/or diinositol phosphate and their equally effective derivatives and/or pharmacologically acceptable salts thereof, for the combating of pulmonary diseases caused by the effect of airborne particles and/or causally related cardiovascular diseases. | 06-23-2011 |
